Investigational combo therapy shows benefit for TP53 mutant MDS and AML patients

(H. Lee Moffitt Cancer Center& Research Institute) Moffitt Cancer Center is leading a national, multicenter clinical trial investigating a new therapy option for this group of patients. It builds upon the standard of care therapy, combining eprenetapopt (APR-246) with the chemotherapy azacitidine. Results of the phase 1b/2 trial to determine the safety, recommended dose and efficacy of the combination therapy were published in the Journal of Clinical Oncology.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news